University of Aberdeen logo

AURA - Aberdeen University Research Archive

 

Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer

Simple item page
dc.contributor.authorPonnusamy, Suriyan
dc.contributor.authorHe, Yali
dc.contributor.authorHwang, Dong-Jin
dc.contributor.authorThiyagarajan, Thirumagal
dc.contributor.authorHoutman, Rene
dc.contributor.authorBocharova, Vera
dc.contributor.authorSumpter, Bobby G.
dc.contributor.authorFernandez, Elias
dc.contributor.authorJohnson, Daniel
dc.contributor.authorDu, Ziyun
dc.contributor.authorPfeffer, Lawrence M.
dc.contributor.authorGetzenberg, Robert H.
dc.contributor.authorMcEwan, Iain J.
dc.contributor.authorMiller, Duane D.
dc.contributor.authorNarayanan, Ramesh
dc.contributor.institutionUniversity of Aberdeen.Medical Sciencesen
dc.date.accessioned2020-09-02T23:06:44Z
dc.date.available2020-09-02T23:06:44Z
dc.date.embargoedUntil2020-09-03
dc.date.issued2019-11
dc.descriptionAcknowledgement. BGS acknowledges work performed at the Center for Nanophase Materials Sciences, a DOE Office of Science User Facility. VB acknowledges Laboratory Directed Research and Development program of Oak Ridge National Laboratory, managed by UTBattelle, LLC, for the U.S. Department of Energy.en
dc.description.statusPeer revieweden
dc.format.extent17
dc.format.extent3710811
dc.identifier146002560
dc.identifier58dca3ef-6c27-4472-aaaf-5883270fbfc8
dc.identifier31481513
dc.identifier85074356016
dc.identifier000497334300024
dc.identifier.citationPonnusamy, S, He, Y, Hwang, D-J, Thiyagarajan, T, Houtman, R, Bocharova, V, Sumpter, B G, Fernandez, E, Johnson, D, Du, Z, Pfeffer, L M, Getzenberg, R H, McEwan, I J, Miller, D D & Narayanan, R 2019, 'Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer', Clinical Cancer Research, vol. 25, no. 22, pp. 6764-6780. https://doi.org/10.1158/1078-0432.CCR-19-1458en
dc.identifier.doi10.1158/1078-0432.CCR-19-1458
dc.identifier.iss22en
dc.identifier.issn1078-0432
dc.identifier.otherMendeley: ff2ee6b2-d612-3083-bd9b-c5945063a762
dc.identifier.urihttps://hdl.handle.net/2164/15067
dc.identifier.urlhttp://www.mendeley.com/research/orallybioavailable-androgen-receptor-degrader-potential-nextgeneration-therapeutic-enzalutamideresisen
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85074356016&partnerID=8YFLogxKen
dc.identifier.vol25en
dc.language.isoeng
dc.relation.ispartofClinical Cancer Researchen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectprostate canceren
dc.subjectCastration-Resistant Prostate Cancer (CRPC)en
dc.subjectandrogen receptor (AR)en
dc.subjectAR degrader (SARD)en
dc.subjectcoactivatoren
dc.subjectenzalutamide-resistant prostate canceren
dc.subjectPHOSPHORYLATIONen
dc.subjectCYP17A1 INHIBITORen
dc.subjectSPLICE VARIANTen
dc.subjectANTITUMOR-ACTIVITYen
dc.subjectDIFFERENTIAL REGULATIONen
dc.subjectBREAST-CANCERen
dc.subjectANTIANDROGENen
dc.subjectGENEen
dc.subjectINCREASED SURVIVALen
dc.subjectABIRATERONEen
dc.subjectRC0254 Neoplasms. Tumors. Oncology (including Cancer)en
dc.subjectOncologyen
dc.subjectCancer Researchen
dc.subjectSupplementary Dataen
dc.subject.lccRC0254en
dc.titleOrally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Canceren
dc.typeJournal articleen

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
221719_1_merged_1562017078.pdf
Size:
3.54 MB
Format:
Adobe Portable Document Format
Download

Collections

All research